Cancer Research UK Manchester Institute
Caroline Dive runs a large multidisciplinary research group (>75 staff) comprised of scientists and clinicians comprised of preclinical pharmacology, circulating cells & proteins and nucleic acids biomarkers research teams. Their preclinical research is focused on developing patient derived models to understand the biology, dissemination and treatment optimization of lung cancer with emphasis on small cell lung cancer. The group also links with clinical colleagues across the UK and globally to evaluate mechanism based therapies in early and late clinical trials with a range of biomarker approaches measured using our a large suite of state of the art technologies. Specifically, the group focus on development, validation and qualification of liquid and tissue biopsies, with a particular emphasis on circulating tumour cells (CTCs) and circulating tumour DNA (ctDNA). Caroline Dive’s group works to Good Clinical Practice for Laboratory (GCPL) standards so that biomarker measurements guide clinical decisions according to EU clinical trials regulations. The research group currently have a portfolio of ~50 clinical trials supported by our biomarker sciences.